Vogler M - Search Results

1

MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.

Bolomsky A, Vogler M, Köse MC, Heckman CA, Ehx G, Ludwig H, Caers J. Bolomsky A, et al. Among authors: vogler m. J Hematol Oncol. 2020 Dec 11;13(1):173. doi: 10.1186/s13045-020-01007-9. J Hematol Oncol. 2020. PMID: 33308268 Free PMC article. Review.

2

Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations.

Henz K, Al-Zebeeby A, Basoglu M, Fulda S, Cohen GM, Varadarajan S, Vogler M. Henz K, et al. Among authors: vogler m. Biol Chem. 2019 Jan 28;400(2):181-185. doi: 10.1515/hsz-2018-0233. Biol Chem. 2019. PMID: 29924730

3

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.

Ewald L, Dittmann J, Vogler M, Fulda S. Ewald L, et al. Among authors: vogler m. Cell Death Dis. 2019 Dec 4;10(12):917. doi: 10.1038/s41419-019-2156-2. Cell Death Dis. 2019. PMID: 31801941 Free PMC article.

4

Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.

Bolomsky A, Vogler M, Köse MC, Heckman CA, Ehx G, Ludwig H, Caers J. Bolomsky A, et al. Among authors: vogler m. J Hematol Oncol. 2021 Feb 17;14(1):31. doi: 10.1186/s13045-021-01043-z. J Hematol Oncol. 2021. PMID: 33596924 Free PMC article. No abstract available.

5

It's time to die: BH3 mimetics in solid tumors.

Kehr S, Vogler M. Kehr S, et al. Among authors: vogler m. Biochim Biophys Acta Mol Cell Res. 2021 Apr;1868(5):118987. doi: 10.1016/j.bbamcr.2021.118987. Epub 2021 Feb 15. Biochim Biophys Acta Mol Cell Res. 2021. PMID: 33600840 Free article. Review.

6

Evaluation and critical assessment of putative MCL-1 inhibitors.

Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM. Varadarajan S, et al. Among authors: vogler m. Cell Death Differ. 2013 Nov;20(11):1475-84. doi: 10.1038/cdd.2013.79. Epub 2013 Jul 5. Cell Death Differ. 2013. PMID: 23832116 Free PMC article.

7

Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.

Vogler M, Walter HS, Dyer MJS. Vogler M, et al. Br J Haematol. 2017 Aug;178(3):364-379. doi: 10.1111/bjh.14684. Epub 2017 Apr 27. Br J Haematol. 2017. PMID: 28449207 Free article. Review.

8

BCL-x_L-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis.

Faqar-Uz-Zaman SF, Heinicke U, Meister MT, Vogler M, Fulda S. Faqar-Uz-Zaman SF, et al. Among authors: vogler m. Cancer Lett. 2018 Jan 1;412:131-142. doi: 10.1016/j.canlet.2017.09.025. Epub 2017 Sep 23. Cancer Lett. 2018. PMID: 28947136

9

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies.

Al-Zebeeby A, Vogler M, Milani M, Richards C, Alotibi A, Greaves G, Dyer MJS, Cohen GM, Varadarajan S. Al-Zebeeby A, et al. Among authors: vogler m. Haematologica. 2019 May;104(5):1016-1025. doi: 10.3324/haematol.2018.204701. Epub 2018 Nov 22. Haematologica. 2019. PMID: 30467206 Free PMC article.

10

Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.

Smith VM, Dietz A, Henz K, Bruecher D, Jackson R, Kowald L, van Wijk SJL, Jayne S, Macip S, Fulda S, Dyer MJS, Vogler M. Smith VM, et al. Among authors: vogler m. Haematologica. 2020 Aug;105(8):2150-2163. doi: 10.3324/haematol.2019.220525. Epub 2019 Oct 10. Haematologica. 2020. PMID: 31601689 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

124 results

Search Page